Get the Weekly Intelligence Brief — top committee picks every Sunday.
COO · NASDAQ · STOCK

Cooper Companies (COO) Stock Analysis

Healthcare Updated October 10, 2026
$54.36
52W $51.01 – $89.83
59/100
$10.60B
18.6
0.82
AI Committee Verdict
Buy
59/100
Conviction: High · 80% agreement · 5 analysts
+36.9%
-5.9%
6.24:1
High

Is COO Bullish or Bearish?

Bullish. Innellis AI committee rates Cooper Companies (The) (COO) Buy with a composite score of 59/100 , based on 5 analysts with 80% agreement. Last updated October 10, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +15.88 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -4.12 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

Supporting evidence favours the bullish case. The main limiting factor is sector concentration is already high (hhi 2796.97). The committee is constructive but not yet at full conviction.

Bull & Bear Case

Bull Case
  • EPS growing 44.2% YoY — Growth
  • 5 consecutive earnings beats -- consistent execution — Growth
  • MACD histogram positive -- bullish momentum — Technical
  • Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
  • Price structure making lower highs and lower lows — Technical
  • RSI at 29 is in oversold territory (could mean either capitulation or a bounce setup) — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of October 10, 2026
Overall Committee Score
59/100
Agreement
80%
Analysts
5
Conviction
High
Sector Rank
Top 37%
of 192 Healthcare peers
Value Analyst bullish
62 / 100 · Moderate confidence
Classic value case: cheap on multiples with earnings power to back it up
Growth Analyst bullish
60 / 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 44.2% YoY
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst neutral
49 / 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
− Price structure making lower highs and lower lows
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst bullish
60 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager bearish
30 / 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 59.1 to 59.1.

Analyst-level changes:
  • Technical Analyst: +1 bearish signal(s).

Comparing 2026-10-09 to 2026-10-10 (1 day apart).

Technical Analysis

RSI (14)
29.4
Oversold
MACD Histogram
0.452
Bullish Momentum
Trend Direction
Downtrend
Weekly: Downtrend
Market Structure
Mixed
Support
$51.15
Resistance
$74.42
Bollinger %B
0.28
Inside Bands
Price vs Moving Averages
EMA 9
$55.54 Below
EMA 21
$57.45 Below
EMA 50
$62.05 Below
EMA 200
$68.83 Below

Fundamental Analysis

Valuation
95
Growth
62
Profitability
55
Financial Health
68
Cash Flow
70
Valuation
P/E Ratio 18.6×
P/B Ratio 1.26×
PEG Ratio 0.43
Dividend Yield 0.00%
52W High $89.83
52W Low $51.01
Quality & Growth
ROE 455.0%
ROA 302.5%
Gross Margin 6364.2%
Operating Margin 1285.3%
Revenue Growth YoY —
Debt / Equity 0.31
AI Fundamental Assessment
P/E ratio of 18.6 (inexpensive relative to a 15-40x range); Price-to-book of 1.3x; PEG ratio of 0.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 4.6%; Return on assets of 3.0%; Net margin of 13.5%; Gross margin of 63.6%; Current ratio of 1.22 (tight short-term liquidity); Debt-to-equity of 0.31; Free cash flow per share is positive (3.51); Most recent quarter beat estimates by 1.8%; 5 consecutive earnings beats; EPS growth decelerating (+10.0% -> -5.0% QoQ); Average YoY EPS growth of 4.5%; Analyst estimates rising over recent quarters
Get the Full COO Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime